MedPath

Korean Cancer Study Group

🇰🇷South Korea
Ownership
-
Established
1998-01-01
Employees
-
Market Cap
-
Website
http://www.kcsg.org/

Clinical Trials

10

Active:1
Completed:1

Trial Phases

4 Phases

Phase 1:2
Phase 2:5
Phase 3:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 2
5 (50.0%)
Not Applicable
2 (20.0%)
Phase 1
2 (20.0%)
Phase 3
1 (10.0%)

Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

Not Applicable
Conditions
Locally Advanced Rectal Cancer
Interventions
First Posted Date
2021-10-15
Last Posted Date
2021-10-15
Lead Sponsor
Korean Cancer Study Group
Target Recruit Count
40
Registration Number
NCT05079503

A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Phase 2
Conditions
DDR Gene Mutation
Metastatic Solid Tumor
Interventions
First Posted Date
2021-02-21
Last Posted Date
2021-02-21
Lead Sponsor
Korean Cancer Study Group
Target Recruit Count
48
Registration Number
NCT04761744
Locations
🇰🇷

Korean Cancer Study Group, Seoul, Chongro-ku, Korea, Republic of

🇰🇷

Korea University Anam Hospital, Seoul, Seongbuk-gu, Inchon-ro, Korea, Republic of

Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients

Phase 1
Active, not recruiting
Conditions
PIK3CA Gene Mutation
Metastatic Colorectal Cancer
Interventions
First Posted Date
2021-02-15
Last Posted Date
2023-10-31
Lead Sponsor
Korean Cancer Study Group
Target Recruit Count
65
Registration Number
NCT04753203
Locations
🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)

Phase 1
Withdrawn
Conditions
Colorectal Cancer Metastatic
Interventions
First Posted Date
2021-02-12
Last Posted Date
2023-10-31
Lead Sponsor
Korean Cancer Study Group
Registration Number
NCT04751955

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Phase 2
Conditions
Metastatic Breast Cancer
HER2-positive Breast Cancer
Interventions
First Posted Date
2018-10-09
Last Posted Date
2021-02-18
Lead Sponsor
Korean Cancer Study Group
Target Recruit Count
15
Registration Number
NCT03698383
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath